This new GLP-1 play is on a tear. UBS sees nearly a 50% gain from here
CNBC Top News ·
MBX Biosciences has more than tripled over the past year, but there's likely more to go as the biotech makes progress on developing a new GLP-1 treatment, according to UBS. …
MBX Biosciences has more than tripled over the past year, but there's likely more to go as the biotech makes progress on developing a new GLP-1 treatment, according to UBS. The investment bank has a buy rating on MBX, and in a report out Monday left a $60 price target on the stock, implying nearly 50% upside from Friday's close. …
Original source: CNBC Top News